Mesoblast Reports 1H 2026 Financial Results with Significant Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy MESO?
Source: seekingalpha
- Disappointing Earnings: Mesoblast's 1H 2026 GAAP EPS of -$3.11 missed expectations by $3.06, indicating significant challenges in achieving profitability amid ongoing operational hurdles.
- Revenue Surge: Despite the disappointing earnings, Mesoblast reported a staggering 1503.1% year-over-year revenue increase to $51.3 million, although it still fell short of the anticipated $54.8 million, highlighting market demand volatility.
- Ryoncil® Gross Profit Improvement: The gross profit from Ryoncil® reached $44.2 million, a substantial increase from nil in the prior year, suggesting growing market acceptance and sales potential for the product.
- Direct Selling Costs: Direct selling costs amounted to $7.7 million, which, while relatively high, indicates that the company's investments in sales and marketing are beginning to yield returns as revenue grows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MESO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MESO
Wall Street analysts forecast MESO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.850
Low
35.00
Averages
35.00
High
35.00
Current: 15.850
Low
35.00
Averages
35.00
High
35.00
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mesoblast Reports 1H 2026 Financial Results with Significant Revenue Growth
- Disappointing Earnings: Mesoblast's 1H 2026 GAAP EPS of -$3.11 missed expectations by $3.06, indicating significant challenges in achieving profitability amid ongoing operational hurdles.
- Revenue Surge: Despite the disappointing earnings, Mesoblast reported a staggering 1503.1% year-over-year revenue increase to $51.3 million, although it still fell short of the anticipated $54.8 million, highlighting market demand volatility.
- Ryoncil® Gross Profit Improvement: The gross profit from Ryoncil® reached $44.2 million, a substantial increase from nil in the prior year, suggesting growing market acceptance and sales potential for the product.
- Direct Selling Costs: Direct selling costs amounted to $7.7 million, which, while relatively high, indicates that the company's investments in sales and marketing are beginning to yield returns as revenue grows.
See More
Mesoblast Reports Strong H1 FY2026 Financial Results Driven by Ryoncil Launch
- Strong Financial Performance: Mesoblast reported total revenue of $51.3 million for H1 FY2026, a significant increase from $3.2 million in the prior year, indicating that the successful commercialization of Ryoncil® has driven substantial revenue growth for the company.
- Successful Ryoncil® Launch: The U.S. commercial launch of Ryoncil® generated gross sales of $57.0 million, with net revenue of $48.7 million after adjustments, and a gross profit of $44.2 million against direct selling costs of $7.7 million, reflecting strong market demand and profitability.
- Increased R&D Investment: The robust operational performance allowed the company to invest in R&D, including supporting a Phase 3 trial for chronic low back pain, aiming to enhance long-term market competitiveness by expanding Ryoncil®'s indications.
- Improved Cash Flow: As of December 31, 2025, Mesoblast had a cash balance of $130 million and secured a $125 million non-dilutive credit line, with expectations of reduced net cash spend in the future, enhancing financial flexibility to support expansion and clinical programs.
See More
Ryoncil Demonstrates High Survival Rates in Acute GVHD Treatment
- Importance of Early Intervention: Ryoncil has demonstrated high survival rates in patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD), emphasizing the need for early use of Ryoncil after steroid resistance to complete the full treatment course and maximize survival chances.
- Clinical Trial Results: Among 53 patients receiving Ryoncil as ≥ third-line treatment for SR-aGvHD, 15% died before completing the full course, compared to only 2% in the Phase 3 trial as second-line treatment, highlighting the significant advantage of early intervention.
- First FDA-Approved MSC Product: Ryoncil is the first mesenchymal stromal cell product approved by the U.S. FDA for any indication and the only product approved for children under 12 with steroid-refractory acute graft-versus-host disease, marking a significant breakthrough in this field.
- Market Performance Analysis: Mesoblast shares are currently trading at $17.73, 1.8% above the 20-day simple moving average but 2.3% below the 50-day moving average, indicating short-term strength while facing medium-term resistance in the market.
See More
Mesoblast Reports Ryoncil® Treatment Data for SR-aGvHD
- Survival Rate Improvement: At the 2026 ASTCT meeting in Salt Lake City, Mesoblast presented data showing that Ryoncil® achieves high survival rates in steroid-refractory acute graft-versus-host disease (SR-aGvHD) patients, regardless of age, emphasizing the critical importance of early intervention to maximize survival chances.
- Treatment Outcome Comparison: Among 53 SR-aGvHD patients receiving Ryoncil® as ≥ third-line treatment, 15% died before completing the treatment course, compared to only 2% in the Phase 3 trial receiving it as second-line therapy, highlighting the significant advantages of early treatment.
- Adult Trial Plans: Mesoblast plans to initiate a pivotal trial for second-line treatment in adults with SR-aGvHD following IRB approval, with enrollment expected to begin this quarter, and if successful, it will support label extension for Ryoncil® in adults, a market approximately three times the size of the pediatric population.
- Platform Technology Advantage: Ryoncil® is the first FDA-approved mesenchymal stromal cell product for SR-aGvHD treatment, showcasing Mesoblast's leadership in cellular therapies and laying the groundwork for future treatments of other inflammatory diseases.
See More
Mesoblast Reports Strong Q2 Performance and Financing Update
- Significant Sales Growth: Ryoncil® achieved gross sales of $35 million for the quarter ending December 31, 2025, reflecting a 60% increase from the prior quarter, indicating sustained market demand and enhancing future revenue sustainability.
- Increased Financing Flexibility: Mesoblast secured a new $125 million non-dilutive credit line at an 8% annual interest rate, significantly reducing financing costs and expected to provide greater flexibility for strategic partnerships and product label expansion.
- Positive Clinical Outcomes: Among the 25 patients treated with Ryoncil®, 84% completed the initial 28-day treatment regimen, demonstrating the product's effectiveness in addressing severe SR-aGvHD, further solidifying its market position.
- Encouraging FDA Feedback: Mesoblast received positive feedback from the FDA regarding the potential filing of a Biologics License Application for rexlemestrocel-L in chronic low back pain patients, which is expected to drive the company's expansion into new markets and enhance product line diversity.
See More
Mesoblast Reports Strong Q2 Performance with Ryoncil Sales Surge
- Significant Sales Growth: Ryoncil® achieved gross sales of $35 million in Q2 2025, reflecting a 60% increase from Q1 2025, indicating strong market demand that is expected to further drive revenue growth for the company.
- Enhanced Financing Flexibility: Mesoblast secured a new $125 million non-dilutive credit line at an 8% annual interest rate, significantly reducing financing costs and enhancing the company's flexibility for strategic partnerships and product expansion.
- Positive Clinical Outcomes: Among the first 25 patients treated with Ryoncil®, 84% completed the 28-day regimen, demonstrating the therapy's effectiveness and likely facilitating the company's pivotal trial for label extension in adults with SR-aGvHD.
- Encouraging FDA Feedback: Mesoblast received positive feedback from the FDA regarding the potential filing of a Biologics License Application for rexlemestrocel-L in chronic low back pain patients, which is expected to further enhance the company's market share in pain management.
See More
Mesoblast Reports 1H 2026 Financial Results with Significant Revenue Growth
- Disappointing Earnings: Mesoblast's 1H 2026 GAAP EPS of -$3.11 missed expectations by $3.06, indicating significant challenges in achieving profitability amid ongoing operational hurdles.
- Revenue Surge: Despite the disappointing earnings, Mesoblast reported a staggering 1503.1% year-over-year revenue increase to $51.3 million, although it still fell short of the anticipated $54.8 million, highlighting market demand volatility.
- Ryoncil® Gross Profit Improvement: The gross profit from Ryoncil® reached $44.2 million, a substantial increase from nil in the prior year, suggesting growing market acceptance and sales potential for the product.
- Direct Selling Costs: Direct selling costs amounted to $7.7 million, which, while relatively high, indicates that the company's investments in sales and marketing are beginning to yield returns as revenue grows.
See More
Mesoblast Reports Strong H1 FY2026 Financial Results Driven by Ryoncil Launch
- Strong Financial Performance: Mesoblast reported total revenue of $51.3 million for H1 FY2026, a significant increase from $3.2 million in the prior year, indicating that the successful commercialization of Ryoncil® has driven substantial revenue growth for the company.
- Successful Ryoncil® Launch: The U.S. commercial launch of Ryoncil® generated gross sales of $57.0 million, with net revenue of $48.7 million after adjustments, and a gross profit of $44.2 million against direct selling costs of $7.7 million, reflecting strong market demand and profitability.
- Increased R&D Investment: The robust operational performance allowed the company to invest in R&D, including supporting a Phase 3 trial for chronic low back pain, aiming to enhance long-term market competitiveness by expanding Ryoncil®'s indications.
- Improved Cash Flow: As of December 31, 2025, Mesoblast had a cash balance of $130 million and secured a $125 million non-dilutive credit line, with expectations of reduced net cash spend in the future, enhancing financial flexibility to support expansion and clinical programs.
See More
Ryoncil Demonstrates High Survival Rates in Acute GVHD Treatment
- Importance of Early Intervention: Ryoncil has demonstrated high survival rates in patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD), emphasizing the need for early use of Ryoncil after steroid resistance to complete the full treatment course and maximize survival chances.
- Clinical Trial Results: Among 53 patients receiving Ryoncil as ≥ third-line treatment for SR-aGvHD, 15% died before completing the full course, compared to only 2% in the Phase 3 trial as second-line treatment, highlighting the significant advantage of early intervention.
- First FDA-Approved MSC Product: Ryoncil is the first mesenchymal stromal cell product approved by the U.S. FDA for any indication and the only product approved for children under 12 with steroid-refractory acute graft-versus-host disease, marking a significant breakthrough in this field.
- Market Performance Analysis: Mesoblast shares are currently trading at $17.73, 1.8% above the 20-day simple moving average but 2.3% below the 50-day moving average, indicating short-term strength while facing medium-term resistance in the market.
See More
Mesoblast Reports Ryoncil® Treatment Data for SR-aGvHD
- Survival Rate Improvement: At the 2026 ASTCT meeting in Salt Lake City, Mesoblast presented data showing that Ryoncil® achieves high survival rates in steroid-refractory acute graft-versus-host disease (SR-aGvHD) patients, regardless of age, emphasizing the critical importance of early intervention to maximize survival chances.
- Treatment Outcome Comparison: Among 53 SR-aGvHD patients receiving Ryoncil® as ≥ third-line treatment, 15% died before completing the treatment course, compared to only 2% in the Phase 3 trial receiving it as second-line therapy, highlighting the significant advantages of early treatment.
- Adult Trial Plans: Mesoblast plans to initiate a pivotal trial for second-line treatment in adults with SR-aGvHD following IRB approval, with enrollment expected to begin this quarter, and if successful, it will support label extension for Ryoncil® in adults, a market approximately three times the size of the pediatric population.
- Platform Technology Advantage: Ryoncil® is the first FDA-approved mesenchymal stromal cell product for SR-aGvHD treatment, showcasing Mesoblast's leadership in cellular therapies and laying the groundwork for future treatments of other inflammatory diseases.
See More
Mesoblast Reports Strong Q2 Performance and Financing Update
- Significant Sales Growth: Ryoncil® achieved gross sales of $35 million for the quarter ending December 31, 2025, reflecting a 60% increase from the prior quarter, indicating sustained market demand and enhancing future revenue sustainability.
- Increased Financing Flexibility: Mesoblast secured a new $125 million non-dilutive credit line at an 8% annual interest rate, significantly reducing financing costs and expected to provide greater flexibility for strategic partnerships and product label expansion.
- Positive Clinical Outcomes: Among the 25 patients treated with Ryoncil®, 84% completed the initial 28-day treatment regimen, demonstrating the product's effectiveness in addressing severe SR-aGvHD, further solidifying its market position.
- Encouraging FDA Feedback: Mesoblast received positive feedback from the FDA regarding the potential filing of a Biologics License Application for rexlemestrocel-L in chronic low back pain patients, which is expected to drive the company's expansion into new markets and enhance product line diversity.
See More
Mesoblast Reports Strong Q2 Performance with Ryoncil Sales Surge
- Significant Sales Growth: Ryoncil® achieved gross sales of $35 million in Q2 2025, reflecting a 60% increase from Q1 2025, indicating strong market demand that is expected to further drive revenue growth for the company.
- Enhanced Financing Flexibility: Mesoblast secured a new $125 million non-dilutive credit line at an 8% annual interest rate, significantly reducing financing costs and enhancing the company's flexibility for strategic partnerships and product expansion.
- Positive Clinical Outcomes: Among the first 25 patients treated with Ryoncil®, 84% completed the 28-day regimen, demonstrating the therapy's effectiveness and likely facilitating the company's pivotal trial for label extension in adults with SR-aGvHD.
- Encouraging FDA Feedback: Mesoblast received positive feedback from the FDA regarding the potential filing of a Biologics License Application for rexlemestrocel-L in chronic low back pain patients, which is expected to further enhance the company's market share in pain management.
See More
